Landis John B. 4
4 · EyePoint Pharmaceuticals, Inc. · Filed Jan 7, 2025
Insider Transaction Report
Form 4
Landis John B.
Director
Transactions
- Exercise/Conversion
Common Stock
2025-01-05+10,000→ 21,400 total - Exercise/Conversion
Restricted Stock Units
2025-01-05−10,000→ 0 totalExercise: $0.00→ Common Stock (10,000 underlying) - Award
Stock Option (Right to Buy)
2025-01-03+40,000→ 40,000 totalExercise: $8.26From: 2026-01-03Exp: 2035-01-03→ Common Stock (40,000 underlying)
Footnotes (1)
- [F1]Fully vested on the one-year anniversary of the grant date.